vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $9.4M, roughly 1.5× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs 75.7%, a 1858.3% gap on every dollar of revenue. Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-2.1M).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
BYFC vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $13.7M |
| Net Profit | $1.0M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | — | -86.5% |
| Net Margin | 1934.0% | 75.7% |
| Revenue YoY | 10.1% | — |
| Net Profit YoY | -21.8% | 179.1% |
| EPS (diluted) | $0.02 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $13.7M | ||
| Q3 25 | $9.0M | $19.1M | ||
| Q2 25 | $8.1M | $8.1M | ||
| Q1 25 | $8.3M | $2.9M | ||
| Q4 24 | $8.6M | — | ||
| Q3 24 | $8.7M | — | ||
| Q2 24 | $8.2M | — | ||
| Q1 24 | $7.8M | — |
| Q4 25 | $1.0M | $10.4M | ||
| Q3 25 | $-23.9M | $-16.3M | ||
| Q2 25 | $752.0K | $-15.8M | ||
| Q1 25 | $-2.7M | $-13.3M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $516.0K | — | ||
| Q2 24 | $256.0K | — | ||
| Q1 24 | $-154.0K | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | -256.2% | -10.1% | ||
| Q2 25 | 12.8% | -177.7% | ||
| Q1 25 | -45.3% | -472.7% | ||
| Q4 24 | 21.7% | — | ||
| Q3 24 | 8.5% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | -2.9% | — |
| Q4 25 | 1934.0% | 75.7% | ||
| Q3 25 | -264.2% | -85.4% | ||
| Q2 25 | 9.3% | -196.0% | ||
| Q1 25 | -32.3% | -452.7% | ||
| Q4 24 | 15.3% | — | ||
| Q3 24 | 5.9% | — | ||
| Q2 24 | 3.1% | — | ||
| Q1 24 | -2.0% | — |
| Q4 25 | $0.02 | $-3.74 | ||
| Q3 25 | $-2.86 | $-0.11 | ||
| Q2 25 | $0.00 | $-0.16 | ||
| Q1 25 | $-0.39 | $-0.18 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $35.3M |
| Total Assets | $1.3B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $137.5M | ||
| Q3 25 | $19.7M | $103.8M | ||
| Q2 25 | $29.5M | $121.6M | ||
| Q1 25 | $15.8M | $89.1M | ||
| Q4 24 | $61.4M | — | ||
| Q3 24 | $97.1M | — | ||
| Q2 24 | $89.8M | — | ||
| Q1 24 | $67.1M | — |
| Q4 25 | $262.8M | $35.3M | ||
| Q3 25 | $261.7M | $-8.1M | ||
| Q2 25 | $284.7M | $7.1M | ||
| Q1 25 | $283.6M | $10.7M | ||
| Q4 24 | $285.0M | — | ||
| Q3 24 | $286.2M | — | ||
| Q2 24 | $282.1M | — | ||
| Q1 24 | $281.1M | — |
| Q4 25 | $1.3B | $154.7M | ||
| Q3 25 | $1.3B | $133.7M | ||
| Q2 25 | $1.2B | $133.8M | ||
| Q1 25 | $1.3B | $103.7M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-2.0M |
| Free Cash FlowOCF − Capex | $-13.0K | $-2.1M |
| FCF MarginFCF / Revenue | -0.1% | -15.3% |
| Capex IntensityCapex / Revenue | 2.6% | 0.7% |
| Cash ConversionOCF / Net Profit | 0.22× | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-2.0M | ||
| Q3 25 | $3.8M | $-17.5M | ||
| Q2 25 | $3.0M | $-14.5M | ||
| Q1 25 | $-4.3M | $29.0M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.8M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | $-13.0K | $-2.1M | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | $-14.9M | ||
| Q1 25 | $-4.4M | $29.0M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | -15.3% | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | -184.0% | ||
| Q1 25 | -52.4% | 988.3% | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | — | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | 0.7% | ||
| Q3 25 | 1.2% | 0.0% | ||
| Q2 25 | 0.2% | 5.0% | ||
| Q1 25 | 0.2% | 0.8% | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
